Biopharma Pharma Pharmacology 
Pharmaceutical Technology
JUNE 24, 2022
invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 invoX Pharma is a fully owned Sino Biopharmaceutical subsidiary. for each share in cash.
pharmaphorum
AUGUST 11, 2022
The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor, blood cancer and non-oncology setting.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
JUNE 16, 2023
Numerous clinical, regulatory and financial factors are behind this digital shift in pharma. And in the first quarter of this year, the largest Series A ever in digital health ($203M) went into a company accelerating clinical trials and drug development.
European Pharmaceutical Review
OCTOBER 27, 2022
Ahead of the world’s largest pharma event, CPHI Frankfurt – hosted at the Frankfurt Messe (1-3 November, 2022) – part i of the CPHI Annual Report looks ahead at the opportunities for biologics outsourcing and contract manufacturing organisastions (CMOs) in 2023. percent in 2022.
Pharmaceutical Technology
MAY 15, 2023
As molecular targeting peptides, anti-cancer peptides penetrate the plasma membrane, nuclear membrane, and mitochondrial membrane of cancer cells, exerting pharmacological activity through various mechanisms (such as inhibiting DNA synthesis and cell division), thus causing apoptosis of cancer cells.
Pharmaceutical Technology
MAY 24, 2023
Several tetrapeptides are pharmacologically active, showing affinity and specificity for multiple receptors in protein-protein signalling. Whilst Abliva and Ambrx Biopharma stand in second and third positions, respectively. Merck 42 Unlock company profile C. Menarini Industrie Farmaceutiche Riunite.
pharmaphorum
DECEMBER 20, 2022
The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. Although, so far efforts to bring a therapy to market have failed.
Expert insights. Personalized for you.
64 
Let's personalize your content